Casgevy and the Dawn of Commercial CRISPR Medicine: What the World's First Gene Editing Drug Approval Means for Pharma

On December 8, 2023, the United States Food and Drug Administration approved Casgevy — a medicine developed by CRISPR Therapeutics and Vertex Pharmaceuticals for the treatment of sickle cell disease. The approval was a milestone in the history of medicine as consequential as the first approval of a monoclonal antibody, the first approval of a gene therapy vector, or the first approval of an mRNA vaccine. For the first time, a medicine that works by precisely editing the DNA of living human cells had regulatory authorisation for commercial sale.

For the pharmaceutical industry, the approval was a signal that could not be ignored. CRISPR medicine was no longer theoretical. It was commercial. And every pharmaceutical company that had been watching from the sidelines — evaluating CRISPR through licensing conversations and early-stage partnerships — was now facing a question with a deadline: where is our CRISPR strategy?

How Casgevy Works

Casgevy treats sickle cell disease by harvesting stem cells from the patient, editing them outside the body using CRISPR-Cas9 to reactivate fetal haemoglobin production, and reinfusing the edited cells back into the patient after conditioning. The reactivated fetal haemoglobin compensates for the defective adult haemoglobin that causes sickle cell disease, providing a functional cure that is durable — potentially permanent — in treated patients.

The treatment process is complex and expensive — currently priced at approximately $2.2 million per patient in the United States — but for a disease that causes severe chronic pain, organ damage, stroke, and premature death, a single treatment providing functional cure represents extraordinary value. And the manufacturing and delivery infrastructure built for Casgevy is the foundation on which future CRISPR medicines will be built.

"Casgevy is not just a drug. It is proof of concept for an entire therapeutic modality. Every genetic disease that has an identified mutation and a patient population of sufficient size is now a potential CRISPR pharmaceutical target."

The Pipeline That Follows

Casgevy was the first approval, but it will not be the last. The CRISPR pharmaceutical pipeline contains programmes targeting dozens of genetic diseases — beta-thalassaemia, Duchenne muscular dystrophy, Huntington's disease, Transthyretin amyloidosis, ATTR cardiomyopathy, various forms of inherited blindness, and multiple oncology indications using CRISPR-edited CAR-T cells. Several of these programmes are in late-stage clinical development and expected to reach regulatory submission within the next few years.

The pharmaceutical companies building this pipeline — and the companies supplying the manufacturing, delivery, clinical, and regulatory infrastructure it requires — need brands and platforms that communicate their CRISPR pharmaceutical expertise with authority. CrisprPharma.com is positioned to be the definitive platform for this industry.